Kimia Biosciences Limited (BOM:530313)
India · Delayed Price · Currency is INR 27.92
+0.74 (2.72%)
At close: Aug 21, 2026
Kimia Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,120 | 1,149 | 1,189 | 1,049 | 1,285 | 1,249 |
| 1,120 | 1,149 | 1,189 | 1,049 | 1,285 | 1,249 | |
Revenue Growth | -6.73% | -3.40% | 13.39% | -18.39% | 2.89% | -5.89% |
Cost of Revenue | 671.92 | 701.19 | 722.18 | 765.16 | 977.05 | 934.67 |
Gross Profit | 448.31 | 447.65 | 467.03 | 283.6 | 308.11 | 314.34 |
Selling, General & Admin | 123.09 | 126.16 | 149.86 | 167.71 | 181.01 | 158.49 |
Other Operating Expenses | 184.34 | 178.82 | 114.68 | 112.6 | 156.53 | 149.35 |
Operating Expenses | 348.29 | 344.11 | 298.32 | 313.23 | 370.86 | 337.25 |
Operating Income | 100.02 | 103.54 | 168.71 | -29.63 | -62.75 | -22.91 |
Interest Expense | -25.99 | -35.16 | -35.33 | -44.46 | -37.41 | -31.01 |
Interest & Investment Income | - | - | 0.22 | 0.37 | 0.29 | 0.31 |
Currency Exchange Gain (Loss) | - | - | 5.89 | -0.75 | -14.54 | 2.41 |
Other Non Operating Income (Expenses) | 8.55 | 16.22 | -3.15 | -0.99 | 0.25 | 0.21 |
EBT Excluding Unusual Items | 82.59 | 84.6 | 136.34 | -75.46 | -114.16 | -50.99 |
Gain (Loss) on Sale of Investments | - | - | - | 0 | 0.03 | 0.02 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.79 |
Other Unusual Items | - | - | - | 3.62 | -9.75 | - |
Pretax Income | 82.59 | 84.6 | 136.34 | -71.84 | -123.88 | -50.18 |
Income Tax Expense | 10.73 | 10.26 | 40.22 | -18.75 | -30.36 | -13.15 |
Net Income | 71.86 | 74.34 | 96.12 | -53.09 | -93.52 | -37.03 |
Net Income to Common | 71.86 | 74.34 | 96.12 | -53.09 | -93.52 | -37.03 |
Net Income Growth | -18.15% | -22.67% | - | - | - | - |
Shares Outstanding (Basic) | 45 | 45 | 47 | 47 | 47 | 47 |
Shares Outstanding (Diluted) | 45 | 45 | 47 | 47 | 47 | 47 |
Shares Change | -4.52% | -4.20% | - | - | - | - |
EPS (Basic) | 1.60 | 1.64 | 2.03 | -1.12 | -1.98 | -0.78 |
EPS (Diluted) | 1.60 | 1.64 | 2.03 | -1.12 | -1.98 | -0.78 |
EPS Growth | -14.20% | -19.21% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 26.83 | 167.15 | 130.28 | -95.82 | 44.17 |
Free Cash Flow Per Share | - | 0.59 | 3.53 | 2.75 | -2.02 | 0.93 |
Gross Margin | 40.02% | 38.96% | 39.27% | 27.04% | 23.97% | 25.17% |
Operating Margin | 8.93% | 9.01% | 14.19% | -2.83% | -4.88% | -1.83% |
Profit Margin | 6.41% | 6.47% | 8.08% | -5.06% | -7.28% | -2.96% |
Free Cash Flow Margin | - | 2.33% | 14.06% | 12.42% | -7.46% | 3.54% |
EBITDA | 140.9 | 142.67 | 200.85 | 2.72 | -30.03 | 6.05 |
EBITDA Margin | 12.58% | 12.42% | 16.89% | 0.26% | -2.34% | 0.48% |
D&A For EBITDA | 40.88 | 39.13 | 32.14 | 32.35 | 32.73 | 28.96 |
EBIT | 100.02 | 103.54 | 168.71 | -29.63 | -62.75 | -22.91 |
EBIT Margin | 8.93% | 9.01% | 14.19% | -2.83% | -4.88% | -1.83% |
Effective Tax Rate | 12.99% | 12.13% | 29.50% | - | - | - |
Revenue as Reported | 1,129 | 1,165 | 1,202 | 1,065 | 1,297 | 1,258 |
Advertising Expenses | - | - | 9.62 | 12.43 | 14.13 | 5.29 |